12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Humira adalimumab regulatory update

The European Commission expanded the label of Abbott's Humira adalimumab to include treatment of patients aged 6-17 years with severely active Crohn's disease who failed, are intolerant to or have contraindications to conventional...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >